Liquidia Corporation

NASDAQ:LQDA

Biotechnology

Healthcare
$56.40 +0.34%

+$0.23 today

Market cap
$5.08B
Beta
0.59
P/E (TTM)
271.8
EPS (TTM)
$0.25
52W Low $11.85High $73.22

Volume 1.22M

Average 1.50M

LQDA Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Liquidia CorporationNASDAQ: LQDA

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q2 FY2026 weighted avg shares (diluted) of 101.4M shares rose 18.5% year over year, ahead of the +16.5% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.3% from the prior quarter. Over 3 fiscal years it compounded at +12.2% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +18.5% holds above the trailing-twelve-month pace of +16.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
101.4M+0.3% QoQ
Last fiscal yearDec 2025
86.06M+9.3% YoY
LTMJun 2026
97.22M+16.5% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+18.5%——
1 year+9.3%——
3-year CAGR+12.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
86.06M USD
Year-over-year change
+9.3%
4-year CAGR
+14.7%

Weighted Avg Shares (Diluted) vs competitors

How LQDA compares with its peers on the latest reported figures

  • LQDA's LTM Jun 2026 weighted avg shares (diluted) of 97.22M shares is the 3rd highest of the 4 companies compared; the peer median is 142.11M shares.
  • Its year-over-year change of +16.5% is the 3rd highest of 4, against a peer median of +18.7%.
  • Over three fiscal years its annual growth of +12.2% compares with a peer median of +20.2%.
LQDA Competitors Peer median
Weighted Avg Shares (Diluted) for LQDA and competitors
Company Period LTM YoY 3-year CAGR
INSMInsmed IncorporatedLTM Jun 2026214.47M +18.7%+20.2%
VCREVicore Pharma Holding ABLTM Jun 2026142.11M +51.7%+47.9%
LQDALiquidia CorporationLTM Jun 202697.22M +16.5%+12.2%
UTHRUnited Therapeutics CorporationLTM Jun 202647.05M -3.0%-0.4%
AVLNAvalyn Pharma Inc. Common Stock—— ——
Peer median (excluding LQDA) 142.11M+18.7%+20.2%

Competitors are the stored peer set for LQDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12.85M15.94M17.49M14M158.32M
Cost of Revenue3.02M2.86M2.89M5.88M13.24M
Gross Profit9.83M13.08M14.6M8.12M145.08M
Gross Margin76.5%82.1%83.5%58.0%91.6%
Research & Development20.52M19.44M43.24M47.84M39.28M
Selling, General & Admin23.11M32.41M44.74M81.57M157.18M
Operating Expenses43.63M51.85M87.98M129.41M196.45M
Depreciation & Amortization5.61M3.65M2.18M2.2M1.53M
EBITDA(28.21M)(35.03M)(70.05M)(115.71M)(43.22M)
EBITDA Margin-219.4%-219.8%-400.6%-826.7%-27.3%
Operating Income(33.8M)(38.77M)(73.38M)(121.29M)(51.38M)
Operating Margin-263.0%-243.3%-419.6%-866.6%-32.5%
Interest Income33K1.09M3.47M7.65M6.62M
Interest Expense762K2.34M6.27M12.49M24.17M
Other Income / Expenses(782K)(2.25M)(5.12M)(9.1M)(17.55M)
Income Before Tax(34.58M)(41.02M)(78.5M)(130.39M)(68.92M)
Pre-Tax Margin-269.0%-257.4%-448.9%-931.7%-43.5%
Income Tax Expense00000
Net Income(34.58M)(41.02M)(78.5M)(130.39M)(68.92M)
Net Margin-269.0%-257.4%-448.9%-931.7%-43.5%
EPS (Basic)(0.70)(0.67)(1.21)(1.66)(0.80)
EPS (Diluted)(0.70)(0.67)(1.21)(1.66)(0.80)
Weighted Avg Shares49.68M60.96M64.99M78.71M86.06M
Weighted Avg Shares (Diluted)49.68M60.96M64.99M78.71M86.06M

Liquidia Corporation

NASDAQ:LQDA

Intrinsic Alpha fair value

Locked

Current Price

$56.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.